Lei Chen

Dr. Lei Chen

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLei Chen
Lei Chen
AEAnna Eriksson
Anna Eriksson
SWSimone Weström
Simone Weström
TPTatjana Pandzic
Tatjana Pandzic
SLSören Lehmann
Sören Lehmann
ULUlf Landegren
Ulf Landegren
Rare tumor-specific mutations in patient samples serve as excellent markers to monitor the course of malignant disease and responses to therapy in clinical routine, and improved assay techniques are needed for broad adoption. We describe herein a highly sensitive and selective molecule amplification technology - superRCA assays - for rapid and highly specific detection of DNA sequence variants present at very low frequencies in DNA samples. Using a standard flow cytometer we demonstrate precise, ultra-sensitive detection of single-nucleotide mutant sequences from malignant cells against up to a 100,000-fold excess of DNA from normal cells in either bone marrow or peripheral blood, to follow the course of patients treated for acute myeloid leukemia (AML). We also demonstrate that sequence variants located in a high-GC region may be sensitively detected, and we illustrate the potential of the technology for early detection of disease recurrence as a basis for prompt change of therapy.

10 January 2019 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
YXYuan Xie
Yuan Xie
ASAnders Sundström
Anders Sundström
NMNaga Prathyusha Maturi
Naga Prathyusha Maturi
ETE‐Jean Tan
E‐Jean Tan
VMVoichita Dana Marinescu
Voichita Dana Marinescu
LULene Uhrbom
Lene Uhrbom

25 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAndries Blokzijl
Andries Blokzijl
LCLei Chen
Lei Chen
SGSigrun M Gustafsdottir
Sigrun M Gustafsdottir
JVJimmy Vuu
Jimmy Vuu
GUGustav Ullenhag
Gustav Ullenhag
HHHåkan Hedstrand
Håkan Hedstrand
The diagnosis of malignant melanoma currently relies on clinical inspection of the skin surface and on the histopathological status of the excised tumor. The serum marker S100B is used for prognostic estimates at later stages of the disease, but analyses are marred by false positives and inadequate sensitivity in predicting relapsing disorder. To investigate SOX10 as a potential biomarker for melanoma and vitiligo. In this study we have applied proximity ligation assay (PLA) to detect the transcription factor SOX10 as a possible serum marker for melanoma. We studied a cohort of 110 melanoma patients. We further investigated a second cohort of 85 patients with vitiligo, which is a disease that also affects melanocytes. The specificity of the SOX10 assay in serum was high, with only 1% of healthy blood donors being positive. In contrast, elevated serum SOX10 was found with high frequency among vitiligo and melanoma patients. In patients with metastases, lack of SOX10 detection was associated with treatment benefit. In two responding patients, a change from SOX10 positivity to undetectable levels was seen before the response was evident clinically. We show for the first time that SOX10 represents a promising new serum melanoma marker for detection of early stage disease, complementing the established S100B marker. Our findings imply that SOX10 can be used to monitor responses to treatment and to assess if the treatment is of benefit at stages earlier than what is possible radiologically.

27 November 2025 in Blood
Verified
Journal Article
Open access
PNPaula Navarro-Navarro
Paula Navarro-Navarro
MGMaría González-Tablas
María González-Tablas
APAlba Pérez-Pons
Alba Pérez-Pons
LSLaura Sánchez-Muñoz
Laura Sánchez-Muñoz
AHAna Henriques
Ana Henriques
AOAlberto Orfao
Alberto Orfao
Detection of KIT p.D816V is a cornerstone in the diagnosis and classification of mast cell activation syndromes (MCAS) and mastocytosis. However, KIT p.D816V may be undetected due to a low mutated-cell burden in the blood and bone marrow (BM) of many patients, particularly those without skin lesions. These findings underscore the need for ultrasensitive molecular techniques for the detection of KIT p.D816V in these clinical settings. Here, we evaluated, to our knowledge, for the first time, the sensitivity and specificity of a novel Flow-SuperRCA KIT p.D816V assay, compared with conventional allele-specific oligonucleotide quantitative polymerase chain reaction (ASOqPCR), through the analysis of 548 blood and BM samples from 337 adult patients with MCAS and mastocytosis. Our results demonstrated greater sensitivity of the new technique vs ASOqPCR (limit of detection: 0.001% vs 0.01% variant allele frequency), with higher rates of positivity for KIT p.D816V in whole blood and/or BM of 64% of patients with monoclonal MCAS and 55% of patients with BM mastocytosis (P< .0001). Notably, the sensitivity of the new assay went beyond that of ASOqPCR in purified BM mast cells (P< .0001). Additionally, clonality was newly identified in 18% of patients previously diagnosed with nonclonal MCAS, who presented with a unique cutaneous MCA-related symptomatic profile. These results confirm the high specificity and ultrasensitivity of the Flow-SuperRCA assay for the detection of KIT p.D816V, emerging as a well-suited whole-blood and whole-BM test for diagnostic screening and classification of patients with MCAS and mastocytosis. These findings further highlight the clonal nature of an unprecedently high fraction of patients who presented with anaphylaxis and MCAS, with important pathogenic, diagnostic, and clinical implications.

1 June 2016 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
ABAndries Blokzijl
Andries Blokzijl
AZAgata Zieba
Agata Zieba
MHMichael Hust
Michael Hust
TSThomas Schirrmann
Thomas Schirrmann
SHSaskia Helmsing
Saskia Helmsing
ULUlf Landegren
Ulf Landegren
The cellular heterogeneity seen in tumors, with subpopulations of cells capable of resisting different treatments, renders single-treatment regimens generally ineffective. Accordingly, there is a great need to increase the repertoire of drug treatments from which combinations may be selected to efficiently target sets of pathological processes, while suppressing the emergence of resistance mutations. In this regard, members of the TGF-β signaling pathway may furnish new, valuable therapeutic targets. In the present work, we developed in situ proximity ligation assays (isPLA) to monitor the state of the TGF-β signaling pathway. Moreover, we extended the range of suitable affinity reagents for this analysis by developing a set of in-vitro-derived human antibody fragments (single chain fragment variable, scFv) that bind SMAD2 (Mothers against decapentaplegic 2), 3, 4, and 7 using phage display. These four proteins are all intracellular mediators of TGF-β signaling. We also developed an scFv specific for SMAD3 phosphorylated in the linker domain 3 (p179 SMAD3). This phosphorylation has been shown to inactivate the tumor suppressor function of SMAD3. The single chain affinity reagents developed in the study were fused tocrystallizable antibody fragments (Fc-portions) and expressed as dimeric IgG-like molecules having Fc domains (Yumabs), and we show that they represent valuable reagents for isPLA. Using these novel assays, we demonstrate that p179 SMAD3 forms a complex with SMAD4 at increased frequency during division and that pharmacological inhibition of cyclin-dependent kinase 4 (CDK4)1 reduces the levels of p179SMAD3 in tumor cells. We further show that the p179SMAD3-SMAD4 complex is bound for degradation by the proteasome. Finally, we developed a chemical screening strategy for compounds that reduce the levels of p179SMAD3 in tumor cells with isPLA as a read-out, using the p179SMAD3 scFv SH544-IIC4. The screen identified two kinase inhibitors, known inhibitors of the insulin receptor, which decreased levels of p179SMAD3/SMAD4 complexes, thereby demonstrating the suitability of the recombinant affinity reagents applied in isPLA in screening for inhibitors of cell signaling.

4 June 2018 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
SLShiyu Li
Shiyu Li
SZShuangshuang Zeng
Shuangshuang Zeng
LCLei Chen
Lei Chen
ZZZhen Zhang
Zhen Zhang
KHKlas Hjort
Klas Hjort
SZShili Zhang
Shili Zhang